CN112266384B - ErbB受体抑制剂 - Google Patents

ErbB受体抑制剂 Download PDF

Info

Publication number
CN112266384B
CN112266384B CN202010657663.6A CN202010657663A CN112266384B CN 112266384 B CN112266384 B CN 112266384B CN 202010657663 A CN202010657663 A CN 202010657663A CN 112266384 B CN112266384 B CN 112266384B
Authority
CN
China
Prior art keywords
compound
alkyl
halogen
group
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202010657663.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112266384A (zh
Inventor
李正涛
钟卫
王家秉
曾庆北
徐汉忠
杨振帆
张小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dizhe Jiangsu Pharmaceutical Co ltd
Original Assignee
Dizhe Jiangsu Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizhe Jiangsu Pharmaceutical Co ltd filed Critical Dizhe Jiangsu Pharmaceutical Co ltd
Publication of CN112266384A publication Critical patent/CN112266384A/zh
Application granted granted Critical
Publication of CN112266384B publication Critical patent/CN112266384B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010657663.6A 2018-05-08 2019-05-08 ErbB受体抑制剂 Active CN112266384B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/085998 2018-05-08
CN2018085998 2018-05-08
PCT/CN2019/085949 WO2019214634A1 (en) 2018-05-08 2019-05-08 Erbb receptor inhibitors
CN201980006431.XA CN111587248A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980006431.XA Division CN111587248A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Publications (2)

Publication Number Publication Date
CN112266384A CN112266384A (zh) 2021-01-26
CN112266384B true CN112266384B (zh) 2022-09-23

Family

ID=68467752

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202010657663.6A Active CN112266384B (zh) 2018-05-08 2019-05-08 ErbB受体抑制剂
CN202010656946.9A Active CN111747953B (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010657654.7A Pending CN111662289A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN201980006431.XA Pending CN111587248A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202010656946.9A Active CN111747953B (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN202010657654.7A Pending CN111662289A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂
CN201980006431.XA Pending CN111587248A (zh) 2018-05-08 2019-05-08 Erbb受体抑制剂

Country Status (15)

Country Link
US (2) US10822334B2 (https=)
EP (2) EP4410291A3 (https=)
JP (2) JP7540953B2 (https=)
KR (1) KR102806778B1 (https=)
CN (4) CN112266384B (https=)
AR (1) AR117424A1 (https=)
AU (1) AU2019267959B2 (https=)
BR (1) BR112020022829A2 (https=)
CA (1) CA3099315A1 (https=)
DK (1) DK3814341T3 (https=)
ES (1) ES2977196T3 (https=)
MX (2) MX2020011868A (https=)
PT (1) PT3814341T (https=)
TW (2) TWI858848B (https=)
WO (1) WO2019214634A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587248A (zh) * 2018-05-08 2020-08-25 迪哲（江苏）医药有限公司 Erbb受体抑制剂

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110357858B (zh) 2018-04-09 2022-02-18 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
WO2019196622A1 (zh) * 2018-04-09 2019-10-17 威尚（上海）生物医药有限公司 具有穿过血脑屏障能力的5取代二氟哌啶化合物
EP4523755A3 (en) * 2018-09-18 2025-06-11 F. Hoffmann-La Roche AG Quinazoline derivatives as antitumor agents
AR117788A1 (es) * 2019-01-14 2021-08-25 Pi Industries Ltd Compuestos de fenilamidina 3-sustituida, preparación y uso
TWI879751B (zh) * 2020-03-23 2025-04-11 印度商皮埃企業有限公司 3-被取代的苯基脒化合物及其製備和用途
CA3194724A1 (en) * 2020-10-05 2022-04-14 Dana-Farber Cancer Institute, Inc. Potent and selective inhibitors of her2
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
IL312004A (en) * 2021-10-20 2024-06-01 Hoffmann La Roche Crystalline forms of quinazoline derivatives, their preparation, assembly and use
CN114262327B (zh) * 2021-12-30 2023-01-03 武汉九州钰民医药科技有限公司 一种her2小分子抑制剂图卡替尼的制备工艺
CN114671867B (zh) * 2022-03-15 2023-09-19 上海法默生物科技有限公司 妥卡替尼中间体7-羟基-[1,2,4]三唑并[1,5-a]吡啶的制备方法
CN118715216A (zh) * 2022-03-28 2024-09-27 江苏恒瑞医药股份有限公司 含氮杂环类化合物、其制备方法及其在医药上的应用
AU2023329558A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
AU2023410324A1 (en) 2022-12-22 2025-05-15 Boehringer Ingelheim International Gmbh Crystalline forms of a her2 inhibitor
CN116102491A (zh) * 2023-02-17 2023-05-12 浙江晖石药业有限公司 一种利用连续流技术进行金属催化偶联的应用
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
CN116903615A (zh) * 2023-06-21 2023-10-20 江苏丽源医药有限公司 一种妥卡替尼及其中间体的制备方法
CN121568696A (zh) 2023-07-28 2026-02-24 勃林格殷格翰国际有限公司 制备her2抑制剂的方法
WO2025051148A1 (zh) * 2023-09-05 2025-03-13 北京鞍石生物科技股份有限公司 含氮杂芳基化合物及其制备方法和应用
CN117534669A (zh) * 2023-11-01 2024-02-09 上海凌凯医药科技有限公司 五元氮杂环并吡啶醇的制备方法
CN117658818B (zh) * 2023-11-03 2025-02-07 江西巍华化学有限公司 一种4-氟-3-硝基三氟甲苯的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585754A (zh) * 2001-11-03 2005-02-23 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
CN101171244A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 用作抗肿瘤药的吲唑基氨基喹唑啉衍生物
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
GB0321648D0 (en) * 2003-09-16 2003-10-15 Astrazeneca Ab Quinazoline derivatives
ATE488513T1 (de) * 2005-09-20 2010-12-15 Astrazeneca Ab 4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
ATE446294T1 (de) * 2005-11-15 2009-11-15 Array Biopharma Inc N4-phenyl-chinazolin-4-aminderivate und verwandte verbindungen als inhibitoren der erbb-typ-i- rezeptortyrosinkinase zur behandlung hyperproliferativer krankheiten
TWI858848B (zh) 2018-05-08 2024-10-11 大陸商迪哲（江蘇）醫藥股份有限公司 ＥｒｂＢ受體抑制劑

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1585754A (zh) * 2001-11-03 2005-02-23 阿斯特拉曾尼卡有限公司 用作抗肿瘤药物的喹唑啉衍生物
CN101171244A (zh) * 2005-03-04 2008-04-30 阿斯利康(瑞典)有限公司 用作抗肿瘤药的吲唑基氨基喹唑啉衍生物
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111587248A (zh) * 2018-05-08 2020-08-25 迪哲（江苏）医药有限公司 Erbb受体抑制剂

Also Published As

Publication number Publication date
US20210009587A1 (en) 2021-01-14
MX2023008954A (es) 2023-08-18
CN111587248A (zh) 2020-08-25
DK3814341T3 (da) 2024-04-22
US11447492B2 (en) 2022-09-20
CN111662289A (zh) 2020-09-15
MX2020011868A (es) 2021-02-26
CN111747953B (zh) 2021-05-07
KR20210013071A (ko) 2021-02-03
ES2977196T3 (es) 2024-08-20
US20200317669A1 (en) 2020-10-08
KR102806778B1 (ko) 2025-05-12
PT3814341T (pt) 2024-04-11
TW202015690A (zh) 2020-05-01
JP2021523159A (ja) 2021-09-02
EP3814341A4 (en) 2022-01-05
AU2019267959A1 (en) 2020-11-26
US10822334B2 (en) 2020-11-03
EP3814341B1 (en) 2024-03-20
AU2019267959B2 (en) 2024-06-06
JP7810734B2 (ja) 2026-02-03
CN112266384A (zh) 2021-01-26
JP2024050653A (ja) 2024-04-10
WO2019214634A1 (en) 2019-11-14
CA3099315A1 (en) 2019-11-14
TW202344253A (zh) 2023-11-16
AR117424A1 (es) 2021-08-04
JP7540953B2 (ja) 2024-08-27
EP3814341A1 (en) 2021-05-05
EP4410291A3 (en) 2024-08-14
EP4410291A2 (en) 2024-08-07
TWI811358B (zh) 2023-08-11
TWI858848B (zh) 2024-10-11
BR112020022829A2 (pt) 2021-02-02
CN111747953A (zh) 2020-10-09

Similar Documents

Publication Publication Date Title
CN112266384B (zh) ErbB受体抑制剂
JP6587116B2 (ja) キナゾリン化合物
EP4491624A1 (en) Heterocyclic compound for inducing degradation of g12d mutant kras protein
CN106459034B (zh) 作为成纤维细胞生长因子受体抑制剂的喹诺酮衍生物
JP7725511B2 (ja) ４－アミノキナゾリン化合物
CN108026095A (zh) 新化合物
US20220411422A1 (en) Erbb receptor inhibitors
HK40045061B (en) Erbb receptor inhibitors
HK40037928B (en) Erbb receptor inhibitors
HK40037928A (en) Erbb receptor inhibitors
HK40045061A (en) Erbb receptor inhibitors
HK40028318A (en) Erbb receptor inhibitors
RU2810215C2 (ru) Ингибиторы рецепторов erbb
HK40028142A (en) Erbb receptor inhibitors
HK40114639A (en) Erbb receptor inhibitors
TWI922584B (zh) 用於誘發g12d突變kras蛋白之分解之喹唑啉化合物
HK40046084B (en) Erbb receptor inhibitors
HK40046084A (en) Erbb receptor inhibitors
HK1254965B (zh) 新化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40045061

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant